Clinical Trial Update: Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors [EARLY_Phase 1]

View source ↗

Summary

An early-phase window-of-opportunity trial assessed whether the PARP inhibitor rucaparib modulates PD-L1 expression in triple-negative breast cancer. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• RUBRACA (RUCAPARIB)

Snippet

Sponsor: University of Arizona | Conditions: Breast Cancer | EARLY_Phase 1 | Status: COMPLETED